Skip to main content
Welcome to
super saver spring
offer ends april 20
save over $140
save over 85%
$0.99
per week for 24 weeks
Welcome to
super saver spring
$0.99
per week
for 24 weeks
// //

A weekly coronavirus testing regime using a “no-swab” saliva test is being trialled in southern England and could result in a simpler and quicker way to detect outbreaks of the virus, the British government said on Monday.

“Saliva testing could potentially make it even easier for people to take coronavirus tests at home, without having to use swabs,” said Health Secretary Matt Hancock.

“This trial will also help us learn if routine, at-home testing could pick up cases of the virus earlier.”

Story continues below advertisement

The tests do not use the standard polymerase chain reaction (PCR) method, which experts say can miss cases because of errors in collecting samples from the back of the throat using a long nasopharyngeal swab.

Instead a different technique, called RT-Lamp, is used in the trial’s saliva test, which the government said had already be shown to be highly promising.

The pilot program will involve further validation of the technique against PCR nasal swabs, it said.

More than 14,000 doctors and health workers, other essential workers and university staff and their households in the city of Southampton will participate in the trial, which uses a test developed by British firm Optigene, the government said.

Rather than taking a swab, which some people find uncomfortable, participants will spit into a pot. Test results will be received within 48 hours, the government said.

The pilot will be jointly led by Southampton City Council, the University of Southampton, and the state-run health service, alongside a wider network of public services in Hampshire.

Last month, the U.S. Food and Drug Administration approved the use of at-home saliva tests to detect the virus in the United States.

Story continues below advertisement

The British government said it was also exploring the potential of other no-swab saliva based coronavirus tests with companies including Chronomics, Avacta, MAP Science and Oxford Nanoimaging (ONI).

It said it was also working with suppliers including DNA Genotek, International Scientific Supplies Ltd, Isohelix and other leading manufacturers, to develop bespoke saliva collection kits and scale up manufacturing for products that can be used with existing PCR tests.

The pilot will run for up to four weeks, testing people on a weekly basis, the government said, resulting in a total of 33,000 – 40,000 tests in the program.

Sign up for the Coronavirus Update newsletter to read the day’s essential coronavirus news, features and explainers written by Globe reporters and editors.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies